Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer

• Status: Recruiting
• Trial end date: 2022-09-15
• Target enrollment: 0
• Participant gender: All

Summary

This is a controlled, open-label, randomized phase- II trial (1:1 randomization) investigating 5-FU + aflibercept and 5-FU + oxaliplatin in elderly and frail elderly patients with mCRC scheduled to receive first line treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest; Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
• Collaborators: Sanofi; STABIL - Statistische und Biometrische Lösungen; Trium Analysis Online GmbH
• Treatments: Aflibercept; Fluorouracil; Folic Acid; Leucovorin; Levoleucovorin; Oxaliplatin

Criteria

Inclusion Criteria:

1. To enter this trial the oncologist has to confirm, that the patient was in his or her opinion not a candidate for standard full-dose combination therapy. Moreover, the oncologist has to state the reason for entering the trial (Advanced age alone versus both age and frailty). As an operational definition for frailty the G8 screening tool will be used upon inclusion of the patient in a standardized manner. Briefly, G8 is an established screening tool that includes seven items from the Mini Nutritional Assessment (MNA) and an age-related item (<80, 80 to 85, or 85 years). The total score can range from 0 to 17. The result on the G8 is considered abnormal if the score is ≤14, indicating a geriatric risk profile.

2. Patients have to have histologically confirmed mCRC with unidimensionally measurable inoperable advanced or metastatic disease

3. ECOG performance status of 2 or better.

4. Life expectancy of 3 months or longer at enrolment

5. Patients >70 years with no upper age limit

6. Previous adjuvant chemotherapy is allowed if completed more than 6 months before randomisation

7. Previous rectal (chemo)radiotherapy is allowed if completed more than 6 months before randomisation

8. Hematological status:

• Neutrophils (ANC) ≥ 1.5 x 109/L

• Platelets ≥ 100 x 109/L

• Hemoglobin ≥ 9 g/dL

9. Adequate renal function:

• Serum creatinine level ≤ 1.5 x upper limit normal (ULN)

10. Adequate liver function:

• Serum bilirubin ≤ 1.5 x upper limit normal (ULN)

• Alkaline phosphatase ≤ 2.5 x ULN (unless liver metastases are present, then < 5 x ULN in that case)

• AST and ALT < 3 x ULN (unless liver metastases are present then < 5 x ULN in that case)

11. Proteinuria < 2+ (dipstick urinalysis) or ≤ 1 g/24hour

12. Signed and dated informed consent, and willing and able to comply with protocol requirements

13. Regular follow-up feasible

14. Male patients with a partner of childbearing potential must agree to use effective contraception (Pearl Index < 1) during the course of the trial and at least 3 months after last administration of the study drug.

Exclusion Criteria:

1. Prior systemic chemotherapy for mCRC

2. Other concomitant or previous malignancy, except:

• Adequately treated in-situ carcinoma of the uterine cervix

• Basal or squamous cell carcinoma of the skin

• Cancer in complete remission for > 5 years

3. Any other serious and uncontrolled non-malignant disease, major surgery or traumatic injury within the last 28 Days

4. History or evidence upon physical examination of CNS metastasis unless adequately treated (irradiation and no seizure with appropriate treatment)

5. Uncontrolled hypercalcemia

6. Pre-existing peripheral neuropathy (NCI grade ≥2)

7. Concomitant protocol unplanned antitumor therapy (e.g. chemotherapy, molecular targeted therapy, immunotherapy),

8. Treatment with any other investigational medicinal product within 28 days prior to study entry.

9. Significant cardiovascular disease:

• Cardiovascular accident or myocardial infarction or unstable angina ≤6 months before start of study treatment

• Severe cardiac arrhythmia

• New York Heart Association grade ≥2 congestive heart failure

• Uncontrolled hypertension (defined as systolic blood pressure >150 mmHg and/or diastolic blood pressure >100 mmHg), or history of hypertensive crisis, or hypertensive encephalopathy.

• History of stroke or transient ischemic attack ≤6 months before start of study treatment

• Coronary/peripheral artery bypass graft ≤6 months before start of study treatment.

• Deep vein thrombosis or thromboembolic events ≤1 month before start of study treatment

10. Patients with known allergy to any excipient to study drugs,

11. Any of the following within 3 months prior to randomization: Grade 3-4 gastrointestinal bleeding/hemorrhage, treatment resistant peptic ulcer disease, erosive oesophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolism or other uncontrolled thromboembolic event.

12. Bowel obstruction.

13. Treatment with CYP3A4 inducers unless discontinued > 7 days prior to randomization

14. Known dihydropyrimidine dehydrogenase (DPD) deficiency

15. Involvement in the planning and/or conduct of the study (applies to both Sanofi staff and/or staff of sponsor and study site)

16. Patient who might be dependent on the sponsor, site or the investigator

17. Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG.

18. Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].